Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Trevena Inc (TRVN)
Trevena Inc (TRVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Trevena: Q1 Earnings Snapshot

Trevena: Q1 Earnings Snapshot

TRVN : 1.1500 (+6.48%)
Aadi Bioscience, Inc. (AADI) Reports Q1 Loss, Tops Revenue Estimates

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 1.72% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AADI : 7.74 (-0.39%)
TRVN : 1.1500 (+6.48%)
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.079 (+1.28%)
SILO : 2.05 (-1.44%)
LLY : 425.79 (-0.36%)
ACOR : 0.5946 (-8.52%)
TRVN : 1.1500 (+6.48%)
IMRN : 1.9501 (+3.73%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

SILO : 2.05 (-1.44%)
LLY : 425.79 (-0.36%)
ACOR : 0.5946 (-8.52%)
TRVN : 1.1500 (+6.48%)
IMRN : 1.9501 (+3.73%)
Trevena (NASDAQ: TRVN) Partner Receives Approval for OLINVYK in China

Trevena, Inc. (NASDAQ: TRVN) is engaged as a biopharmaceutical company, which is focused on the research, development and commercialization of

TRVN : 1.1500 (+6.48%)
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 0% and 5.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

KNSA : 14.07 (+2.18%)
TRVN : 1.1500 (+6.48%)
Trevena: Q4 Earnings Snapshot

Trevena: Q4 Earnings Snapshot

TRVN : 1.1500 (+6.48%)
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate

Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.

TRVN : 1.1500 (+6.48%)
CRSP : 64.66 (+1.27%)
KALA : 15.05 (+1.96%)
ALLO : 5.53 (+1.10%)
Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TRVN : 1.1500 (+6.48%)
SPRO : 1.7700 (+1.14%)
Trevena: Q3 Earnings Snapshot

Trevena: Q3 Earnings Snapshot

TRVN : 1.1500 (+6.48%)

Barchart Exclusives

Gold Update – An Explosive Rally Gets Delayed
The continuous gold futures contract rose to an ominous price in May 2023, reaching $2,072 per ounce. The rally took gold to a level creating a technical pattern that sticks out like a sore thumb on the long-term chart. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar